Clinical stage biopharmaceutical company Acrivon Therapeutics Inc (Nasdaq:ACRV) announced on Tuesday that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, a multiplex immunofluorescence assay designed to identify ovarian cancer patients who may benefit from ACR-368 treatment.
This designation acknowledges the FDA's belief that the device could enhance the treatment or diagnosis of life-threatening or irreversibly debilitating human diseases.
Based on the Acrivon Predictive Precision Proteomics (AP3) platform, the ACR-368 OncoSignature assay is being used in Acrivon's ongoing Phase 2 trial to predict patient responses to the CHK1/2 inhibitor ACR-368 across three tumour types. The AP3 platform is also used more broadly to uncover resistance mechanisms and rational drug combinations, and for biological rational drug design for Acrivon's drug candidates.
Acrivon has partnered with spatial phenotyping specialist Akoya Biosciences Inc (NASDAQ:AKYA) to co-develop, validate and commercialise the ACR-368 OncoSignature assay.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration